CN103608016A - 丙酮酸激酶激活剂在治疗中的用途 - Google Patents
丙酮酸激酶激活剂在治疗中的用途 Download PDFInfo
- Publication number
- CN103608016A CN103608016A CN201280028693.4A CN201280028693A CN103608016A CN 103608016 A CN103608016 A CN 103608016A CN 201280028693 A CN201280028693 A CN 201280028693A CN 103608016 A CN103608016 A CN 103608016A
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyl
- carbonyl
- quinoline
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 Cc(cc(cc1)C(P(CC2)CC*2C2CC2)=*)c1*([N+]([O-])=O)=C Chemical compound Cc(cc(cc1)C(P(CC2)CC*2C2CC2)=*)c1*([N+]([O-])=O)=C 0.000 description 3
- LHHQXDZYDFSYTK-UHFFFAOYSA-N C/C=S/Nc(c(OC(F)(F)F)c1)ccc1C(N(CC1)CCN1C(OC1COCC1)=O)=O Chemical compound C/C=S/Nc(c(OC(F)(F)F)c1)ccc1C(N(CC1)CCN1C(OC1COCC1)=O)=O LHHQXDZYDFSYTK-UHFFFAOYSA-N 0.000 description 1
- YKNBQZUCCSBZEA-UHFFFAOYSA-N CC(C)(c1ccccc1F)N(CC1)CCN1C(c(cc1)cc([O]=S=O)c1Nc1cccc2c1nccc2)=O Chemical compound CC(C)(c1ccccc1F)N(CC1)CCN1C(c(cc1)cc([O]=S=O)c1Nc1cccc2c1nccc2)=O YKNBQZUCCSBZEA-UHFFFAOYSA-N 0.000 description 1
- ZBSYMYROECDZJU-UHFFFAOYSA-N CC(CN(Cc(c(F)c1)cc(F)c1F)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O Chemical compound CC(CN(Cc(c(F)c1)cc(F)c1F)CC1)N1C(c(cc1)ccc1NS(=O)=O)=O ZBSYMYROECDZJU-UHFFFAOYSA-N 0.000 description 1
- QGUJNNKGNHHUIW-TUHHEGBISA-N CCC(CC=CC=C1S(Nc(c(OC(F)(F)F)c2)ccc2C(N(CC2)C=CN2C2(CC2)c2ccc(C)cc2)=O)(=O)=O)=C1/N=C\C Chemical compound CCC(CC=CC=C1S(Nc(c(OC(F)(F)F)c2)ccc2C(N(CC2)C=CN2C2(CC2)c2ccc(C)cc2)=O)(=O)=O)=C1/N=C\C QGUJNNKGNHHUIW-TUHHEGBISA-N 0.000 description 1
- UKZONYSVMBRMGQ-UHFFFAOYSA-N O=C(c(cc1)ccc1NS(=O)=O)N(CC1)CCN1C(c1ccncc1F)=O Chemical compound O=C(c(cc1)ccc1NS(=O)=O)N(CC1)CCN1C(c1ccncc1F)=O UKZONYSVMBRMGQ-UHFFFAOYSA-N 0.000 description 1
- TVHSJDPDMUDZJZ-UHFFFAOYSA-N O=C(c(nc1)cnc1NS(c1cccc2c1nccc2)(=O)=O)N1CCN(Cc(cc2)ccc2F)CC1 Chemical compound O=C(c(nc1)cnc1NS(c1cccc2c1nccc2)(=O)=O)N1CCN(Cc(cc2)ccc2F)CC1 TVHSJDPDMUDZJZ-UHFFFAOYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161482166P | 2011-05-03 | 2011-05-03 | |
| US61/482,166 | 2011-05-03 | ||
| PCT/US2012/036413 WO2012151452A1 (en) | 2011-05-03 | 2012-05-03 | Pyruvate kinase activators for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103608016A true CN103608016A (zh) | 2014-02-26 |
Family
ID=46085224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280028693.4A Pending CN103608016A (zh) | 2011-05-03 | 2012-05-03 | 丙酮酸激酶激活剂在治疗中的用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9404081B2 (https=) |
| EP (1) | EP2704720B1 (https=) |
| JP (2) | JP6267112B2 (https=) |
| CN (1) | CN103608016A (https=) |
| AU (1) | AU2012250690B2 (https=) |
| CA (1) | CA2834692A1 (https=) |
| ES (1) | ES2746558T3 (https=) |
| WO (1) | WO2012151452A1 (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032045A (zh) * | 2017-08-15 | 2020-04-17 | 安吉奥斯医药品有限公司 | 用于治疗血液病症的丙酮酸激酶激活剂 |
| CN111892599A (zh) * | 2020-08-14 | 2020-11-06 | 黄芳 | 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法 |
| CN113646050A (zh) * | 2019-02-13 | 2021-11-12 | 安吉奥斯医药品有限公司 | 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途 |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| RU2561132C2 (ru) | 2009-06-29 | 2015-08-20 | Аджиос Фармасьютикалз, Инк. | Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности |
| EP3561077B1 (en) | 2009-10-21 | 2022-12-21 | Les Laboratoires Servier | Methods for cell-proliferation-related disorders |
| WO2012088314A1 (en) | 2010-12-21 | 2012-06-28 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) * | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| ES2746558T3 (es) * | 2011-05-03 | 2020-03-06 | Agios Pharmaceuticals Inc | Activadores de piruvato cinasa R para uso en terapia |
| SG194697A1 (en) * | 2011-05-03 | 2013-12-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| SG10201707409PA (en) | 2013-03-13 | 2017-10-30 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| KR20240010105A (ko) | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| FR3030516B1 (fr) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| FI3307271T3 (fi) * | 2015-06-11 | 2023-10-17 | Agios Pharmaceuticals Inc | Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä |
| SG11201803088PA (en) | 2015-10-15 | 2018-05-30 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4147700A1 (en) * | 2021-09-08 | 2023-03-15 | LQT Therapeutics Inc. | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002817A1 (en) * | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| EP0912519A1 (en) | 1996-05-20 | 1999-05-06 | Darwin Discovery Limited | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| IL158590A0 (en) | 2001-06-11 | 2004-05-12 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| ATE467616T1 (de) | 2003-04-11 | 2010-05-15 | High Point Pharmaceuticals Llc | Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase |
| GB0412526D0 (en) | 2004-06-05 | 2004-07-14 | Leuven K U Res & Dev | Type 2 diabetes |
| US7829712B2 (en) | 2004-09-20 | 2010-11-09 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| WO2007008143A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| AU2006283846B2 (en) | 2005-08-26 | 2012-04-05 | Merck Serono Sa | Pyrazine derivatives and use as PI3K inhibitors |
| JP2010508300A (ja) | 2006-10-26 | 2010-03-18 | フライン、ギャリー・エー． | アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法 |
| HUP0600810A3 (en) * | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| CN105193799A (zh) | 2006-12-08 | 2015-12-30 | 米伦纽姆医药公司 | 使用经口因子xa抑制剂治疗血栓形成的单位剂量调配物和方法 |
| AU2010223919B2 (en) | 2009-03-13 | 2016-03-31 | Les Laboratoires Servier | Methods and compositions for cell-proliferation-related disorders |
| WO2010129596A1 (en) | 2009-05-04 | 2010-11-11 | Agios Pharmaceuticals, Inc. | Pmk2 modulators for use in the treatment of cancer |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| CA2773561A1 (en) | 2009-09-14 | 2011-03-17 | Phusis Therapeutics Inc. | Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same |
| EP2491030B1 (en) | 2009-10-22 | 2015-07-15 | Fibrotech Therapeutics PTY LTD | Fused ring analogues of anti-fibrotic agents |
| AU2011223790A1 (en) * | 2010-03-01 | 2012-08-30 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| ES2746558T3 (es) | 2011-05-03 | 2020-03-06 | Agios Pharmaceuticals Inc | Activadores de piruvato cinasa R para uso en terapia |
| SG194697A1 (en) * | 2011-05-03 | 2013-12-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
-
2012
- 2012-05-03 ES ES12721111T patent/ES2746558T3/es active Active
- 2012-05-03 EP EP12721111.8A patent/EP2704720B1/en active Active
- 2012-05-03 AU AU2012250690A patent/AU2012250690B2/en not_active Ceased
- 2012-05-03 WO PCT/US2012/036413 patent/WO2012151452A1/en not_active Ceased
- 2012-05-03 CN CN201280028693.4A patent/CN103608016A/zh active Pending
- 2012-05-03 JP JP2014509459A patent/JP6267112B2/ja not_active Expired - Fee Related
- 2012-05-03 CA CA2834692A patent/CA2834692A1/en not_active Abandoned
- 2012-05-03 US US14/115,292 patent/US9404081B2/en not_active Expired - Fee Related
-
2016
- 2016-09-05 JP JP2016173166A patent/JP6267299B2/ja not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002817A1 (en) * | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032045A (zh) * | 2017-08-15 | 2020-04-17 | 安吉奥斯医药品有限公司 | 用于治疗血液病症的丙酮酸激酶激活剂 |
| CN111032045B (zh) * | 2017-08-15 | 2023-08-15 | 安吉奥斯医药品有限公司 | 用于治疗血液病症的丙酮酸激酶激活剂 |
| CN113646050A (zh) * | 2019-02-13 | 2021-11-12 | 安吉奥斯医药品有限公司 | 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途 |
| CN111892599A (zh) * | 2020-08-14 | 2020-11-06 | 黄芳 | 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法 |
| CN111892599B (zh) * | 2020-08-14 | 2023-01-13 | 黄芳 | 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016199597A (ja) | 2016-12-01 |
| JP2014513134A (ja) | 2014-05-29 |
| EP2704720B1 (en) | 2019-08-07 |
| CA2834692A1 (en) | 2012-11-08 |
| EP2704720A1 (en) | 2014-03-12 |
| WO2012151452A1 (en) | 2012-11-08 |
| JP6267112B2 (ja) | 2018-01-24 |
| JP6267299B2 (ja) | 2018-01-24 |
| AU2012250690A1 (en) | 2013-11-14 |
| ES2746558T3 (es) | 2020-03-06 |
| AU2012250690B2 (en) | 2017-06-08 |
| US9404081B2 (en) | 2016-08-02 |
| US20140155408A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103608016A (zh) | 丙酮酸激酶激活剂在治疗中的用途 | |
| CN103491960B (zh) | 治疗化合物和组合物 | |
| US20210198206A1 (en) | Therapeutic compounds and compositions | |
| KR101553418B1 (ko) | 피리다지논 유도체 | |
| CN101679303B (zh) | 哒嗪酮衍生物 | |
| CN102264727B (zh) | 哒嗪酮衍生物 | |
| RS54882B1 (sr) | Derivati piramidina kao fak inhibitori | |
| HK1194985A (en) | Pyruvate kinase r activators for use in therapy | |
| HK1194985B (en) | Pyruvate kinase r activators for use in therapy | |
| HK1190342A (en) | Pyruvate kinase m2 (pkm2) activators for use in therapy | |
| HK1190342B (en) | Pyruvate kinase m2 (pkm2) activators for use in therapy | |
| HK1203491A1 (en) | Pyrazinamide compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140226 |